Thus, although EPAS1 (HIF2α gene) is expressed at lower levels than HIF1A in AML cell lines and patients (Fig EV1D and E), we confirmed that tampering HIF2α expression has important phenotypic consequences in AML, as previously observed by us and others (Rouault‐Pierre et al, 2013; Coltella et al, 2014). This evidence concerns the gene HIF1A and acute myeloid leukemia.